TLR9 and Acute hepatitis: Administration of the anti-TLR9 mAb protected mice from acute hepatitis caused by the TLR9 ligand and D-(+)-galactosamine, and these results demonstrate that the anti-TLR9 mAb is a promising tool to control TLR9-dependent inflammatory diseases.